Accessibility navigation


Therapeutic patents for the treatment of pre-eclampsia

Page, N. M. (2004) Therapeutic patents for the treatment of pre-eclampsia. Expert Opinion on Therapeutic Patents, 14 (11). pp. 1579-1591. ISSN 1354-3776

Full text not archived in this repository.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Abstract/Summary

Pre-eclampsia (PE) is a pregnancy-specific syndrome that is a principal cause of maternal morbidity and mortality, accounting for almost 15% of pregnancy-associated deaths. In its mild form, PE most commonly presents with the features of maternal hypertension and proteinuria but can swiftly and unpredictably become severe with many extensive and life-threatening complications. The diverse symptoms of PE have made it a difficult disease not only to define, but also to identify a causative agent for the symptoms. It has therefore proved difficult to develop specific drugs that can be used to manage the condition. This review examines the patent literature to reveal current findings that exhibit the potential to target the effects of PE with the aim of either preventing or altering the course of this life-threatening disease of pregnancy.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Life Sciences > School of Biological Sciences
ID Code:10569
Uncontrolled Keywords:angiotensin, anti-inflammatory calcitonin gene-related peptide, digoxin, endothelin (ET), hypertension, magnesium, neurokinin B, nitric, oxide, pre-eclampsia (PE), pregnancy, prostaglandins, trophoblast, vascular endothelial growth factor, ENDOTHELIAL GROWTH-FACTOR, COLONY-STIMULATING FACTOR, PREGNANCY-INDUCED, HYPERTENSION, SOLUBLE GUANYLATE-CYCLASE, NITRIC-OXIDE SYNTHESIS, LOW, PLATELET COUNT, NEUROKININ-B, RELAXING FACTOR, MAGNESIUM, SUPPLEMENTATION, NORMOTENSIVE PREGNANCIES

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation